Title:Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Volume: 17
Issue: 14
Author(s): Mahdi Shabani and Mohammad Hojjat-Farsangi
Affiliation:
Keywords:
Cancer, monoclonal antibody, receptor tyrosine kinase, targeted therapy.
Abstract: Receptor tyrosine kinases (RTKs) family is comprised of different cell
surface glycoproteins. These enzymes participate in and regulate vital processes
such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling,
and cell survival. Dysregulation of RTKs contributes to the development of different
types of tumors. RTKs deregulation in different types of cancer has been reported
for more than 30 RTKs. Due to their critical roles, the specific targeting of
RTKs in malignancies is a promising approach. Targeted cellular and molecular
therapies (personalized medicine) have been known as new types of therapeutics,
which prevent tumor cell proliferation and invasion by interfering with molecules
essential for tumor growth and survival. Specific targeting of RTKs using monoclonal
antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The
growing number of mAbs approved by the authorities implies on the increasing attentions and applications
of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances
that target RTKs expressed on the tumor cell surface. In this communication, we review the recent
progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
